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The Use of Omega-3 Fatty Acids in
Mental Illness
Jessica L. Go¨ren, PharmD, BCPP1,2,3 and Ashley T. Tewksbury, BS4
Abstract
Purpose: This article will summarize the current evidence on the effects of omega-3 fatty acids on prevention and treatment of
mental illness. Background: Omega-3 fatty acids are involved in many physiologic processes. Since they cannot be made de novo
in the body, they are considered essential nutrients. As the Western diet evolved, dietary intake of fatty acids has shifted to
increased omega-6 fatty acids and decreased omega-3 fatty acids intake. These changes have been correlated with numerous dif-
ferences in prevalence and course of mental illnesses. Methods: A MEDLINE search from 1966 to December 2010 was completed
to identify studies comparing changes in symptoms, functioning, other outcomes, and/or side effects in patients treated with
omega-3 fatty acids for mental illness. The studies were reviewed and reported by specific psychiatric disorder studied.
Conclusions: Omega-3 fatty acids play a role in many biologic functions. Epidemiologic data implicate omega-3 fatty acid deficiencies
in many mental illnesses. Data are most robust for omega-3 fatty acids’ role in affective disorders. However, data are conflicting,
negative, or absent for most mental illnesses.
Keywords
omega-3, fatty acids, omega-6, mental illness, polyunsaturated
Introduction
Fatty acids can be divided into 2 categories, based on chemical
properties (1) saturated fatty acids, which are usually solid at
room temperature and (2) unsaturated fatty acids, which are
liquid at room temperature. Carbon atoms in saturated fats are
bound to 4 other atoms and cannot bind with other atoms.
Unsaturated fatty acids can bind with other atoms due to double
bonds linking at least 1 pair of carbon.
Based on the number of double bonds present, unsaturated
fatty acids are either monounsaturated (contains 1 double bond)
or polyunsaturated (containing >1 double bond). Plant oils such
as olive and canola oils are made up of monounsaturated fatty
acids. Vegetable-, nut-, and seed-based oils such as corn, sun-
flower, walnut, and flax seed oils consist of polyunsaturated
fatty acids (PUFAs). Polyunsaturated fats are further defined
by the location of the first double bond. Omega-6 fatty acids’
double bonds begin at the sixth carbon atom, while omega-3
fatty acids’ double bonds begin with the third carbon atom.
Examples of omega-6 fatty acids are the short chain linoleic
acid (LA) and the longer chain gamma linoleic (GLA) and
arachidonic (AA) acids. Omega-3 fatty acids include alpha-
linolenic acid (ALA), a short chain omega-3 fatty acid, and
long chain omega-3 fatty acids eicosapentaenoic (EPA), doco-
sapentaenoic acid (DPA), and docosahexaenoic (DHA).
The human body cannot make the short chain ALA and LA
fatty acids, and so they are considered essential nutrients. The
long chain omega-6 (GLA and AA) and omega-3 fatty acids
(EPA, DPA, and DHA) can be formed in the body from LA and
ALA. However, only 10% to 15% of ALA can be converted
into EPA, DPA, or DHA in vivo.1 Therefore, the majority of
long-chain fatty acids are derived from dietary sources.1-4,7-9
When a person is deficient in omega-3 fatty acids, there is
increased incorporation of omega-6 fatty acids in cell mem-
branes leading to stiffer, less flexible cell membranes.1-3,7-10
Thus, the ratio of omega-6 fatty acids to omega-3 fatty acids
is essential for normal neuronal functioning.
PUFAs are precursors of eicosanoids, a group of bioactive
mediators involved in inflammation, immunity, and coagula-
tion (Figure 1).2 Series 1 prostaglandins and thromboxanes and
series 4 leukotrienes are derived from AA. AA-derived eicosa-
noids respond to stress or injury producing an array of effects
on clotting, muscle contractility, and cellular influx/efflux of
substances such as calcium. These effects are modulated by the
EPA-derived series 3 prostaglandins and thromboxanes and
series 5 leukotrienes. EPA-derived eicosanoids have less potent
effects or prevent the effects of AA-derived eicosanoids. Thus,
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adequate production of EPA-derived eicosanoids is necessary
for proper functioning of AA-derived eicosanoids.1-7
DHA is converted into the docosanoids, a group of bioactive
molecules possessing anti-inflammatory and neuroprotective
properties. Resolvins, one type of docosanoids, are important
in counteracting proinflammatory responses to omega-6 fatty
acids.4-7 Consequently this cytoprotective function is also
heavily dependent on the omega-6 to omega-3 ratio.1,3
DHA is an integral component of neuronal development and
maturation.1,2,8 Consequently, DHA is an important fatty acid
for learning and neuronal growth and development during the
fetal and infant stages.3 Maternal DHA deficiency during preg-
nancy and lactation may lead to lower cognitive performance
later in childhood.
Neuronal membrane fluidity is dependent on the type of
fatty acid incorporated into the cell membrane. DHA and EPA
are incorporated into neuronal cell membranes and allow the
membrane to be fluid or ‘‘flexible.’’ Such membrane fluidity
is necessary for proper functioning of lipid messengers which
signal cascades leading to changes in neuronal flexibility and
function. This is important in psychiatric illnesses because ser-
otonin and catecholamine receptors, ion channels, transporters,
and G-coupled proteins are dependent on fluid or flexible cell
membranes.
Omega-3 fatty acids are also involved in many physiologic
processes outside the central nervous system. EPA and DHA
enhance nitric oxide production, which may be responsible for
improved endothelial function and arterial compliance.11,12
Alterations in the metabolism of adhesion molecules by DHA
and EPA may inhibit new arterial plaque development.13,14
Inhibition of voltage-gated sodium channels may account for
reductions in arrhythmias with omega-3 fatty acid supplemen-
tation.15 While omega-3 fatty acids influence platelet aggrega-
tion, recent studies have failed to find a correlation between
omega-3 fatty acids and coagulation factors.16 Although earlier
studies have reported omega-3 fatty acids affect platelet aggre-
gation through reductions in thromboxane, a proaggregatory
eicosanoid and inhibition of cyclooxygenase enzymes associ-
ated with thrombosis.17 However, the US Food and Drug
Administration (FDA) has designated omega-3 fatty acids as
‘‘generally recognized as safe’’ when taken at normal doses.18
Taken together, omega-3 fatty acid appears to be safe and ben-
eficial in cardiac disease.18
The source of omega-3 fatty acids is important. Epidemiolo-
gic data indicate both plant- (ALA) and marine (DHA and
EPA)-derived omega-3 fatty acids are important for physiolo-
gic processes.19 However, the preponderance of data indicate
fish-derived omega-3 fatty acids are preferable to plant-
derived omega-3 fatty acids. This is reflected in the American
Psychiatric Association’s recommendations that (1) all adults
eat a variety of fish (preferably oily fish) 2 or more times
weekly; (2) patients with mood, impulse-control, and psychotic
disorders consume 1 g of EPA þ DHA daily; and (3) a supple-
ment may be useful in patients with mood disorders.19
Since omega-3 fatty acids are essential nutrients, changes in
diet can have profound effects on omega-3 fatty acid concen-
trations. The ratio of omega-6 to omega-3 fatty acid intake has
shifted dramatically in the Western diet over several decades.
Omega-3 Fatty Acids         Omega-6 Fatty acids
alpha-linolenic acid         linoleic acid 
stearidonic acid         gamma-linolenic acid (GLA) 
eicosatetraenoic acid    1- series prostaglandins  dihomo-gamma-linolenic acid – DHGLA 
      & thromboxanes 
eicosapentaenoic acid (EPA)   3-series prostaglindins  arachidonic acid (AA) 
      & thromboxanes,  
series-5 leukotrienes   2-series prostaglandins & thromboxanes, 
4-series leukotrienes 
docosapentaenoic acid (DPA) 
docosanoids
Figure 1. Polyunsaturated fatty acids.
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Currently in many Western countries the omega-6 to omega-3
intake ratio is 10:1, while a ratio of 1:1 may be more appropri-
ate.16 Given omega-3 fatty acids’ beneficial effects on multiple
neuronal and cardiovascular targets, it is not surprising that
dietary changes are implicated in both psychiatric and cardio-
vascular disorders.
Methods
In order to determine whether omega fatty acids are a reason-
able treatment option for psychiatric disorder, we conducted
a systematic review of the medical literature. In January
2011, we conducted a MEDLINE search from 1966 to Decem-
ber 2010 to identify studies of omega-3 fatty acids as treatment
or prevention of psychiatric illnesses. The following search
terms were used: omega-3 fatty acid, eicosapentaenoic (EPA),
docosahexaenoic (DHA), mental illness, psychiatry, affective
and mood disorders, psychosis, schizophrenia, anxiety, sub-
stance abuse, attention-deficit hyperactivity disorder (ADHD),
autism, Asperger’s, bipolar disorder, depression, perinatal and
postpartum depression, and personality disorder. The reference
section of these articles and previous reviews were searched for
articles not identified in the original search. Articles were
restricted to the English language. Data on study design, PUFA
treatment, and side effects were abstracted and reported.
We examined studies within strata reflecting the rigor of
their study design: randomized controlled trials (RCTs), non-
randomized controlled studies, and noncontrolled observa-
tional studies. Because of the robust number of studies with
one of these designs, we excluded case reports and series with-
out statistical analyses. Major limitations of each study are
noted in the evidence tables; these include small sample sizes
in some studies, limited matching characteristics, and short
periods before follow-up assessment. Unless otherwise noted,
all comparisons reported were statistically significant.
Unipolar Depression
Most epidemiologic data support the link between fish con-
sumption and a lowered risk of depression.20-28 Consumption
of seafood at least twice a week may be associated with a lower
risk of depression and suicidal ideation.23,24 Severity of depres-
sive symptoms has been linked to the omega-6 to omega-3
ratio.25,26 Many studies suggest a link between depression and
reduced omega-3 fatty acid concentrations in plasma, serum
phospholipids, and red blood cells.21-28 The one large trial that
failed to replicate these findings may have been confounded by
the high average daily intake of omega-3 fatty acids across the
population.29 Studies report mixed outcomes for the interaction
of gender and omega-3 fatty acid concentrations on depression.
One study reported increased fish intake was associated with
less depression in women but not men,20 while another study
found depression was inversely related to omega-3 intake in
boys aged 12 to 15 years.28
Antidepressant response has been postulated to be associ-
ated with omega-3 fatty acid concentrations, although results
from clinical trials have been mixed (Table 1).30-45 Of the 7
augmentation studies in adults, 4 found no benefit with the
addition of omega-3 fatty acids.30,31,32,35 However, 2 of these
studies were in patients with comorbid diabetes or coronary
heart disease and may not be applicable for depressed patients
without these comorbidities.30,31 The 2 positive placebo-
controlled studies reported a 7.2- to 10.8-point improvement
on the Hamilton Depression Rating scale (HAMD) compared
with placebo.33,36 The 1-dose finding trial reported significant
benefit only in the low-dose (1 g) group.34
Of the 8 double-blind trials of omega-3 fatty acids as mono-
therapy for depression, 6 were placebo controlled.39-41,43-45
One randomized, double-blind trial compared omega-3 fatty
acids, fluoxetine and the combination.38 The remaining rando-
mized trial was a dose finding trial and did not include a pla-
cebo group.
Five of the trials, including the largest study, reported no
benefit of omega-3 fatty acids in depression.39-41,43,45 How-
ever, one of the negative trials studied ‘‘mental well-being’’
in those 65 years and another studied psychological dis-
tress.39,45 Both may not adequately address the use of omega-
3 fatty acids in patients with major depression. The remaining
trials differed significantly in terms of specific omega-3 fatty
acids and dose studied, making generalization problematic.
One trial included fluoxetine as an active comparator.38 The
authors reported 1 g of EPA and 20 mg fluoxetine had similar
effects, while the combination was superior to either alone.
The final controlled study of omega-3 fatty acids was a dose
finding study of DHA in adults with depression.42 Doses
included were 1, 2, and 4 g daily. All 3 doses were beneficial
but the most improvement was seen on the 1-g dose, suggesting
there may be a ceiling effect of DHA supplementation.
The only RCT in children was omega-3 fatty acid augmen-
tation of ongoing antidepressant treatment.37 The population
was predominately male. The study found significant benefit
on all outcome measures. The authors point out that the study
had an unexpectedly low placebo response rate which may
have affected the results.
The role of omega-3 fatty acids in unipolar depression is
promising. Epidemiologic data support the theory that
omega-3 fatty acid deficiency is associated with increased rates
of depression. However, clinical trials report varied outcomes.
This may be due to the heterogeneity of trials reported in the
literature. Studies differed in which omega-3 fatty acid or
combinations of fatty acids were used. Augmentation trials
typically enrolled patients regardless of their baseline antide-
pressant. Doses studied varied widely, with total daily doses
up to 9.6 g. A wide variety of depressive disorders were studied
including major depressive disorder, less severe forms of
depression, and depression with comorbid medical illnesses.
Although most studies were in adult patients, age groups stud-
ied ranged from pediatric to geriatric populations. In addition,
trials reported on outcomes of omega-3 fatty acid monother-
apy, omega-3 fatty acid augmentation of specific antidepres-
sant, and combinations of any pre-study antidepressant and
omega-3 fatty acids. While doses ranged widely, all studies
Go¨ren and Tewksbury 3
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reported the use of EPA, DHA, or their combination, so
fish-derived omega-3 fatty acids would seem to be preferable
to plant-derived ALA.
While it is difficult to draw any firm conclusions about
omega-3 fatty acids in unipolar depression, given the safety,
cardioprotective effects, and suggestion that there may be some
benefits with omega-3 fatty acid augmentation or monotherapy
in depression, it seems reasonable to consider omega-3 fatty
acids as a treatment option for patients with depression. They
have a potential role as antidepressant augmentation or mono-
therapy for adults in whom antidepressants are not acceptable.
Given the disparity of data, it is difficult to recommend
specific doses or combinations of fatty acids. It has been sug-
gested that EPA may be the effective component in depression
treatment.46 But, animal models suggest that DHA-deficient
diets are associated with abnormal dopaminergic and seroto-
nergic function.47 Clinical trial data suggest that higher doses
may not confer additional benefits and a daily total of omega-3
fatty acids (EPA/DHA) of 1 to 2 g is reasonable in unipolar
depressive illnesses. While the one trial of omega-3 fatty acids
in children was positive, it is premature to recommend its use
as a therapeutic option in pediatric depression. However, since
omega-3 fatty acids have been proven safe in many other
pediatric conditions, it is unlikely their use in pediatric popu-
lations would be harmful.
Perinatal Depression
Normal neurodevelopment in utero is dependent on adequate
supply of DHA.1,2,8 Hibbeln and Davis suggest that during
pregnancy, as DHA is transferred to the fetus, women with
low-DHA intake will become depleted and more vulnerable
to depression.48 This is supported by epidemiologic data indi-
cating higher intake of fish during pregnancy is associated with
decreased risk of postpartum depression.49,50 Countries with
low fish intake have a 50-fold increased risk of postpartum
depression compared with countries with high seafood
intake.49 Single women with low seafood intake who smoke
may be more likely to have depressive symptoms during preg-
nancy.51 Still other studies report lower concentrations of DHA
in women who develop postpartum depression than those who
do not.50 Some studies have failed to find an association of
omega-3 fatty acid intake and perinatal depression. One study
of 80 women was probably underpowered to find a relation-
ship, while another study had relatively high-baseline rates of
seafood consumption.51,52 The largest study, a prospective
cohort study of 54 202 Danish women, did not support the
inverse relationship of fish or omega-3 fatty acid intake and
postpartum depression.53
Potential risk of low DHA intake extends beyond mothers to
their offspring. Lower verbal intelligence quotient (IQ),
increased risk of fine motor deficits, and behavioral problems
have been reported in children born to women with low seafood
intake during pregnancy.54,55 Hibbeln and Davis calculated
900 mg/d per 2000 calories from seafood is likely sufficient
to provide optimal neurodevelopment in the offspring and
decrease the risk of postpartum depression.48 They also report
that there is no evidence indicating an upper limit of intake for
omega-3 fatty acids as there are no data indicating an excess of
omega-3 fatty acids contribute to neurodevelopment or psy-
chiatric risks.
Interventional trials of omega-3 fatty acid supplementation
during pregnancy have reported mixed outcomes (Table 2).56-62
Six randomized studies were placebo controlled and 1 was a
randomized dose ranging study.
Freeman et al reported significant benefit of omega-3 fatty
acid supplementation in women randomized to 1 of 3 doses
of EPA and DHA.57 However, the study lacked a placebo group
and was not confirmed in more rigorous trials. Llorente and
colleagues found 16 weeks of 200 mg was not associated with
changes in rates of postpartum depression.59 However, the
study had a low baseline level of depression in both groups and
of those with depressive symptoms at baseline, the majority
reported only mild symptoms. Four other RCTs also failed to
find the benefits of omega-3 fatty acid supplementation on
depressive symptoms,56,58,60,61 while 1 small trial reported
benefit with DHA supplementation.62
The largest randomized, double-blind, placebo-controlled
trial found supplementation with 900 mg/d of omega-3 fatty
acids did not prevent postpartum depression in 2399 women.60
During the trial, women were supplemented with omega-3 fatty
acids during the second half of pregnancy. Adherence was con-
firmed by increased concentrations of DHA in the cord blood
of women in the active treatment arm compared with controls
(7.2% vs 6.09%; P < .001). The results may have been con-
founded by an unusually low rate of maternal depression in the
control group. The authors did report a nonsignificant trend
toward decreased depression in women who had been previous
medically diagnosed with depression.
While the role of omega-3 fatty acids in perinatal depres-
sion is supported by epidemiologic data, this has not been
born out in interventional trials. The largest study of
omega-3 fatty acid supplementation in pregnancy failed to
find an effect of omega-3 fatty acids in perinatal depression.
This study utilized a dose consistent with the 900 mg/d per
2000 calories suggested by researchers as likely to meet the
nutritional requirements for 97.5% of pregnant women.48
These findings are in direct contrast to some groups recom-
mending routine omega-3 fatty acid supplementation for
pregnant women. However, it is important to remember the
risk to the fetus and some data indicate poor cognitive out-
comes in children born to women with low omega-3 fatty
acid intake. Overall, while the benefit of omega-3 fatty acids
in perinatal depression, primarily DHA, is not supported by
controlled trials, it is likely that normal neurocognitive devel-
opment is dependent upon adequate maternal DHA concen-
trations. Given the safety of omega-3 fatty acids, effects in
fetal development and general medical benefits such as
improved cardiovascular health, DHA supplementation dur-
ing pregnancy is reasonable. While there are no clear guide-
lines as to dose, Hibbeln and Davis’ work support the use of
900 mg/d per 2000 calories of DHA during pregnancy.48
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Bipolar Disorder
Abnormalities in the omega-6 fatty acid, AA, are thought to
play a role in the pathogenesis of bipolar disorder.63,64 This has
been demonstrated in several studies finding products of AA
are increased in the blood, saliva, and cerebrospinal fluid of
patients with bipolar disorder.63 While omega-3 and omega-6
fatty acids both increase the proinflammatory eicosanoids,
those derived from omega-6 fatty acids result in more inflam-
mation than those derived from omega-3 fatty acids. So, in peo-
ple with high omega-6:omega-3 fatty acid ratios, one would
expect increased inflammation and possibly increased neuronal
cell death.63,64 Ideally, a shift in dietary intake to increased
omega-3 fatty acids would decrease inflammation associated
with omega-6 fatty acids.
This is supported by commonly used treatments for bipolar
disorder which have a similar effect as omega-6 and omega-3
fatty acids (eg, lithium, carbamazepine, and valproate). In ani-
mal models it has been found that these medications decrease
the turnover of the omega-6 fatty acid, AA, and may improve
symptoms of bipolar disorder through secondary decreases in
proinflammatory by-products of AA.63,64
Epidemiologic studies also support the link of omega-
6:omega-3 fatty acid ratios in bipolar disorder. In one cross-
national study, seafood consumption was inversely related to
rates of bipolar I, bipolar II, and bipolar spectrum disorders.65
The relationship seemed strongest with bipolar II disorder. The
authors reported a minimum consumption of 50 pounds of fish
per year, which they estimate is equal to 3 g of EPA/DHA
daily, was associated with decreased rates of bipolar disorders.
Some studies have reported lower concentrations of omega-3
fatty acids in patients being treated for bipolar disorder,
although other studies have not replicated these findings.66-68
Clayton et al found no differences in omega-3 fatty acid con-
centrations in pediatric bipolar disorder when controlling for
the intake of omega-3 fatty acids.69 Rather, the authors suggest
that the high cost of fresh fish and low socioeconomic status
often associated with bipolar disorder may account for the
lower concentrations of omega-3 fatty.
Omega-3 fatty acid concentrations have been correlated with
symptom severity in bipolar disorder. Clayton reported that in
pediatric bipolar disorder, DHA concentrations were associated
with depression severity; while EPA concentrations were more
closely associated with manic symptoms.70 These results were
replicated in a study of adults with bipolar disorder that reported
omega-3 fatty acid concentrations and omega-6:omega-3 ratio
were associated with severity of manic symptoms.71
Three open-label trials have found adjunctive omega-3 fatty
acid supplementation to be effective in bipolar disorder (Table
3).72-80 The two studies in pediatric patients with bipolar disorder
both reported improvement in manic symptoms, one of which
reported improvements in depression when omega-3 fatty acids
were added to ongoing treatment.70,79 The one open-label adult
trial reported significant improvement in depressive symptoms
when omega-3 fatty acids were added to ongoing treatment.75
Results frommore rigorous studies havebeenmixed (Table 3).
Three RCTs reported no benefit, while 2 reported improvements
with omega-3 fatty acid augmentation in adults with bipolar dis-
order.72-74,76,77 Two negative trials studied omega-3 fatty acid
supplementation in subpopulations (acute mania, women discon-
tinuing mood stabilizers prior to becoming pregnant), making it
difficult to generalize the findings.72,76 Both positive trials
reported significant improvement in depressive symptoms but
no benefit for mania, suggesting omega-3 fatty acids may play
a limited role in adult bipolar disorder.73,77
The one randomized controlled trial on pediatric bipolar
disorder reported no benefit with ALA supplementation. How-
ever, overall illness and manic symptoms improved in patients
with significant increases in EPA concentrations.78
Given the disparity in methods, populations studied, and
outcomes, it is difficult to draw any firm conclusions about the
relationship of omega-6:omega-3 fatty acids and bipolar disor-
der. While epidemiologic data indicate that there is a relation-
ship, other studies controlling for omega-3 fatty acid intake do
not find a similar association. In positive studies, data indicate
either 2 to 4 g daily intake of EPA alone or in combination with
DHA are beneficial in adults in the depressive phase of the
illness.
Schizophrenia
Alterations in neuronal membranes and fatty acid metabolism
have been implicated in the pathogenesis of schizophrenia.80,81
Omega-3 fatty acids are known to effect membrane fluidity,
dopaminergic and serotonergic systems, and modulate AA
release, all of which are proposed to be altered in patients with
schizophrenia. In addition, through modulation of glutathione,
omega-3 fatty acids are also thought to be involved in neuronal
protection from excitotoxic and oxidative stress.82-85
Such theorized deficiencies have been supported by clinical
data. Deficiencies in AA, an omega-6 fatty acid, and the
omega-3 fatty acids such as EPA and DHA have been reported
in drug-naive and medicated patients with schizophrenia when
compared with matched controls and patients with bipolar dis-
order.86-88 Patients with schizophrenia and tardive dyskinesia
have also been shown to have decreased concentrations of ery-
throcyte omega-6 fatty acids.89
These findings are supported by studies which report that
lowered dietary intake of fatty acids is associated with psycho-
tic symptoms and the course of schizophrenia.90,91 One study
of 33 000 women with a low intake of omega-3 fatty acids were
found to have an increased risk of psychotic symptoms.92
Another study reported significant deficiencies in a woman’s
diet during pregnancy may increase the risk of schizophrenia
in her children.93 Omega-3 fatty acid supplementation may pre-
vent or delay the onset of schizophrenia (Table 4).94,95 In
patients at high risk of psychosis, Amminger and colleagues
reported 4.9% of EPA/DHA-treated patients and 27.5% of
placebo-treated patients developed psychotic symptoms dur-
ing 40 weeks.94 Peet reported 57% and 100% of EPA- and
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placebo-treated patients required an antipsychotic at the end of
12 weeks.95
Six studies have been reported assessing the role of adj-
unctive omega-3 fatty acids for the treatment of psychosis
(Table 4).96-101 One open-label study reported significant
improvements in general psychopathology with omega-3 fatty
acid supplementation.96 Of the 5 RCTs, 2 were negative,97,99 2
were positive,98,100 and 1 found benefits only when omega-3
fatty acids were added to clozapine.101 Post hoc analyses of one
of the negative studies did report omega-3 supplementation
was beneficial in nonaffective psychosis and associated with
a 20% decrease in total antipsychotic dose.97 Other studies
report differential effects by concomitant antipsychotics with
one reporting benefit only in patients treated with clozapine
and another reporting increased benefits in augmentation of
conventional antipsychotics.98,101 The one study of both EPA
and DHA found EPA significantly better than DHA.100
The role of omega-3 and omega-6 fatty acid supplementa-
tion on side effects in patients with schizophrenia has been
assessed in 3 RCTs.102-104 These trials found no difference in
side effects, extrapyramidal side effects, and tardive dyskinesia
with active treatment and placebo. However, all of these trials
were small and of short duration. Emsley et al did find
increased bleeding time, body mass index, and decreased
high-density lipoprotein (HDL) concentrations in patients pre-
and post-EPA supplementation.103
Studies assessing prevention of psychosis with omega-3
fatty acid supplementation are promising. Although far from
conclusive, data suggest omega-3 fatty acids are more benefi-
cial for nonaffective psychoses. Studies of omega-3 fatty acid
treatment of schizophrenia are mixed. Data suggest EPA is
more effective than DHA monotherapy. Given the cardiovas-
cular benefits and limited side effects of omega-3 fatty acids
when compared to antipsychotics, supplementation with EPA
or EPA/DHA combination in 1 to 2 g daily is reasonable for the
prevention and adjunctive treatment of psychosis. However,
caution should be used in patients at risk of bleeding.
Attention-Deficit Hyperactivity Disorder
In the brain, the principle fatty acid is DHA which increases in
the frontal cortex during childhood and adolescence.105 This
deposition of DHA is associated with neurocognitive matura-
tion.105,106 Disruption in the DHA accumulation in the matur-
ing brain can lead to cognitive and physical problems.105,106 It
has been postulated that altered fatty acid concentrations are
associated with symptoms of attention-deficit hyperactivity
disorder (ADHD).107 Most, but not all studies, report lower
concentrations of omega-6 fatty acids, DHA and EPA, and
higher omega-6:omega-3 fatty acid ratio in children with
ADHD.107 In addition, low concentrations of omega-3 fatty
acids have been observed in the plasma phospholipids and ery-
throcytes of subjects with ADHD.108 In children, studies indi-
cate alterations of omega-3 fatty acids are related to cognitive
problems of ADHD, while changes in omega-6 fatty acids are
associated with physical deficits.109,110 This is supported by
one functional magnetic resonance imaging study reporting
DHA supplementation increased prefrontal cortex activation
during sustained attention in healthy boys.105 Symptom sever-
ity may be related to omega-3 plasma concentrations in chil-
dren.110 Although, one study in adults failed to find an
association of omega-3 fatty acid concentrations in adults with
ADHD.111
All placebo-controlled studies are in pediatric ADHD
(Table 5).112-125 Few report significant improvements in pri-
mary outcome measures with active treatment. Half of the trials
failed to find a significant benefit with omega-3 supplementa-
tion, while others found benefits in subpopulations, mildly ill
children, or for limited symptoms only.112,116,117,120,121,123,125
There were no differences between groups in trials that distin-
guished between inattentive and hyperactive types. Several of
the trials were for disorders related to ADHD. Many studies
were limited by small sample size, making interpretation of
negative findings difficult. Of the studies with positive find-
ings, most reported benefit for inattention only.114,121,122
Current evidence does not support a role of omega-3 fatty
acids in the treatment of ADHD. However, many studies were
limited by small sample size or populations without a clear
diagnosis of ADHD. Though, generally well tolerated, routine
recommendation of omega-3 fatty acids for the treatment of
pediatric ADHD is premature. Given the lack of studies in
adults, omega-3 fatty acids should not be recommended for the
treatment of adult ADHD.
Autism Spectrum Disorders
The term autism spectrum disorder (ASD) encompasses a
range of neurodevelopmental disorders, all of which involve
impairment in social interaction, struggles with verbal and non-
verbal communication, and stereotyped, repetitive behavioral
patterns.126 Classical ASD, or autistic disorder, is diagnosed
when these symptoms manifest in their most severe form. Cur-
rently, Asperger’s disorder has distinct Diagnostic and Statisti-
cal Manual of Mental Disorders (Fourth Edition [DSM-IV])
criteria, with the most notable difference being the absence
of a delay in communicative abilities.127 Individuals with ASD
characteristics who do not identify with either of 2 subcate-
gories are typically given a diagnosis of pervasive developmen-
tal disorder, not otherwise specified (PDD-NOS).128 Although
the average age of diagnosis is 3 years, marked behavioral dis-
parities have been observed in children younger than 12
months.129,130
The proposed etiologies of ASDs cover a broad range,
including abnormalities in metabolism, inflammatory markers,
genetics, neurotransmitter systems, and oxidative stress.131-133
For instance, it has been suggested that inflammation and apop-
tosis play a significant role in autism,133,134 while omega-3
fatty acids have been shown to prevent neuronal apopto-
sis135,136 and influence neuroinflammation.136 Functional poly-
morphisms in serotonin (5-HT) and dopamine (DA)
transporters have been noted in autism,137 while omega-3 fatty
acids have been shown to affect 5-HT and DA neurotransmitter
Go¨ren and Tewksbury 11
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systems.137,138 Fatty acids have wide implications in brain
development and subsequent behavior, including the ability
to respond to external stimuli, while abnormal responses to
environmental stimulation are characteristic of autism.139,140
In addition, low concentrations of omega-3 fatty acids have
been observed in the plasma phospholipids and erythrocytes
of subjects with ADHD,108 a neurodevelopmental disorder
with clinical presentation and genetic biomarkers comparable
to that of autism.141-143
Children with autism have been shown to have 20% lower
omega-3 fatty acid plasma concentrations compared with men-
tally retarded controls.144 The same trial reported no significant
difference in the omega-6 fatty acid concentrations, which
resulted in a significant increase in the omega-6:omega-3 ratio
in the group with autism. Sliwinski et al analyzed plasma sam-
ples from high-functioning adolescent males and a healthy con-
trol group.145 They discovered a statistically significant
increase in plasma DHA, total omega-3 fatty acids, and the
omega-6/omega-3 ratio in the autistic subjects. Wiest et al
reported differences in omega-3 fatty acid concentrations were
not significant when accounting for dietary intake.144
Risperidone, a common drug therapy in ASD, may influence
fatty acid profiles as well. Studies have demonstrated that
chronic therapy with risperidone normalizes inflammatory bio-
markers, significantly affects ALA-DHA biosynthesis, and
increases omega-3 composition of peripheral and central mem-
branes in rats with omega-3 fatty acid deficiency.146,147 Risper-
idone also appears to have a wider range of symptom
improvement, including aggressiveness, hyperactivity, irrit-
ability, stereotypy, social withdrawal, and lack of interests, as
compared to omega-3 fatty acids which only specifically
improve hyperactivity.148
Two trials analyzed fatty acid compositions of red blood
cells rather than plasma concentrations. Bell et al had positive
findings, demonstrating that subjects with autism had signifi-
cantly elevated concentrations of EPA and DHA and signifi-
cantly reduced concentrations of AA.149 They observed
significantly higher percentages of omega-6 fatty acids and
total saturates in the red blood cell membranes of subjects with
regressive autism in particular, when compared to controls. Bu
et al also encountered notable differences in omega-6 fatty acid
profiles between children with clinical regression autism and
those with early onset autism.150 These findings indicate a
potential differential etiology between classical, typical onset,
autism and regressive autism, which develop after initial child
development.
A collection of open-label pilot studies came to disparate
conclusions. Johnson et al did not observe any clinical gains
in autistic children given omega-3 supplements.151 Politi et al
did not observe any statistically significant improvements in
autistic adults after omega-3 treatment, utilizing the Rossago
Behavioral Checklist.152 However, the problematic behaviors
addressed by this instrument are only a portion of autism’s
symptomatic picture. In contrast, Meiri et al observed a statis-
tically significant improvement in subjects treated with omega-
3 fatty acids.153 Meguid et al also observed positive results in
autistic children administered with a preparation of both
omega-3 and omega-6 fatty acids.154 Beneficial effects of
omega-3 supplementation in children were also demonstrated
in an open-label trial by Patrick and Salik, who specifically
looked at language and learning skills.155
RCTs investigating the effects of omega-3 fatty acid treat-
ment in autism are limited (Table 6).151-157 One RCT reported
no significant difference between autistic subjects treated with
omega-3 fatty acids as compared to placebo.156 However, there
were nonsignificant reductions in hyperactivity and stereotypy
subscales. Another randomized control trial noted improve-
ments, including nonsignificant decreases in hyperactivity,
with omega-3 treatment.158 This trial was unique in that it ana-
lyzed cytokines as a biomarker of anti-inflammation effects of
omega-3 treatment. Surprisingly, there was a statistically sig-
nificant increase in the tumor necrosis factor-a (TNF-a) plasma
concentrations in the treatment group as compared to placebo.
One cytokine, interleukin 2 (IL-2), demonstrated a negative
correlation with hyperactivity.
In summary, 4 of the 7 clinical trials demonstrated statisti-
cally significant changes. The lack of positive findings in the
remaining trials is inadequate to fully discredit omega-3 fatty
acids’ potential benefit in improving symptoms of autism. Non-
significant conclusions could be attributed to insufficient
omega-3 dosing or improper EPA/DHA ratios. In addition,
variability in results could be attributed to the presence or
absence of vitamin E, which some trials included in their treat-
ment arm to avoid lipid peroxidation. It is plausible that the
treatment durations were too brief to allow substantial
improvements to take place. However, Meiri et al declared that
most of the improvements they observed occurred within the
first 6 weeks, although raw data for this were not reported.153
Several drug classes are typically used to manage some
behavioral manifestations of autism, including antipsychotics,
psychostimulants, antiepileptics, and antidepressants. Unfortu-
nately, the side effects of these medications are often a limiting
factor.158 More trials are warranted, particularly in adult popu-
lations, before an unequivocal conclusion can be made regard-
ing omega-3’s role in therapy. However, as omega-3 fatty acids
are fairly innocuous, inexpensive, and readily available, a trial
of omega-3 fatty acids in autistic children may be appropriate.
Combinations of EPA and DHA showed the greatest benefit.
Unfortunately, there is insufficient evidence to define a single
most-effective dose or ratio. Children tolerated doses as high as
840 mg EPA and 700 mg DHA. However, trials administering
doses as low as 52 mg EPA and 90 mg DHA yielded positive
results. These particular trials also administered vitamin E
(5 or 10 mg/d), which suggests a dose-sparing effect.155,156
There is evidence for EPA/DHA ratios between 1.5:1 and
2:1, although this is from only 2 trials.154,156 Those considering
a trial treatment with omega-3 fatty acids should consult a
health care practitioner prior to initiating therapy, as the FDA
has not approved the use of fish oil supplements in children
(<18 years). Omega-3 fatty acids’ inhibition of platelet aggre-
gation warrants precaution in those at an increased risk of
bleeding or being treated with anticoagulants.157
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Anxiety Disorders
There are limited studies of omega-3 fatty acid supplementa-
tion in anxiety disorders. Many of the studies address only a
select population. In terms of active treatment, a study of 126
university students with significant test anxiety reported 3
weeks of omega-3/omega-6 supplementation was associated
with improved appetite, mood, organization, and concentration
compared with placebo.159 The authors also reported a signif-
icant decrease in salivary cortisol with active treatment. This
finding should be interpreted with caution since the placebo-
treated students had nonsignificant decreases in salivary corti-
sol as well.
Compared with placebo, anger and anxiety have also been
reported to decrease with omega-3 fatty acid supplementation
in men with substance abuse.160 Researchers found 3 months
of EPA/DHA supplementation decreased the anxiety scores
in patients with substance abuse compared with placebo. The
differences in anxiety symptoms remained significant for 3
months following the discontinuation of the supplements.
Studies of omega-3 fatty acids in obsessive compulsive dis-
order are limited. Fux and colleagues reported EPA supple-
mentation was ineffective for the treatment of obsessive
compulsive disorder.161
Results regarding omega-3 fatty acid supplementation in
posttraumatic stress disorder (PTSD) are conflicting. One study
was terminated early when 2 g daily intake of EPA was found
to worsen symptoms in 5 of 6 patients.162 However, Matsuoka
et al reported open-label treatment with omega-3 fatty acids
could decrease the risk of subsequent PTSD in patients with
accidental injuries.163
Data are too limited to assess the efficacy of omega-3 fatty
acids in the treatment of anxiety disorders. While they may be
beneficial in those with comorbid mood and anxiety disorders,
omega-3 fatty acids should not be routinely used for patients
with PTSD.
Other Disorders
Omega-3 fatty acids have been explored in a limited fashion in
many disorders including substance abuse and borderline per-
sonality disorder. However, there are insufficient data to draw
any conclusions about the effectiveness of omega-3 fatty acids
in these disorders. Omega-3 fatty acids have been studied
extensively in cognition, cognitive decline, dementia, Alzhei-
mer’s disease, and cognitive symptoms associated with other
disorders. This is beyond the scope of this review.
Safety of Omega-3 Fatty Acids
Clinical trials demonstrate the risk of serious adverse events
with omega-3 fatty acids are comparable with placebo. The
most common side effects reported were gastrointestinal (diar-
rhea and belching). The FDA has recognized intakes up to 3 g/d
of omega-3 fatty acids are safe.19 The FDA has also recognized
and approved qualified health claims for EPA and DHA.19 One
study did report an increase in bleeding time after EPA
supplementation, but this increase did not result in clinical side
effects.90 However, other studies report no changes in bleeding
time.75 In one large study of pregnant women there was no
increase in the rate of bleeding with omega-3 fatty acid supple-
mentation.60 In fact, the study found decreased rates of preterm
labor with omega-3 fatty acid supplementation.
While fish may be contaminated with heavy metals, omega-
3 fatty acid supplements usually contain very limited quantities
of organochloride contaminants and no methylmercury.168
However, significant levels of contaminants have been
reported with some supplements.163,164 While omega-3 fatty
acid purification processes substantially decrease the risk of
environmental contamination, krill oil can be used as an alter-
nate source of marine-derived fish oils for those who remain
concerned.165 For those wishing to increase omega-3 fatty acid
intake through fish consumption, the FDA recommends avoid-
ing fish high in methylmercury such as shark, swordfish, king
mackerel, or tilefish.166 Instead consider recommending fish
low in methylmercury content such as shrimp, canned light
tuna, salmon, pollock, and catfish.166
Conclusions
Omega-3 fatty acids have been studied in numerous disease
states. They have cardioprotective effects and are relatively
safe and inexpensive. In general, omega-3 fatty acids were well
tolerated by many groups including pediatric and geriatric
populations. While safe when taken in usual daily doses, cau-
tion should be used with large doses in patients at risk of bleed-
ing abnormalities. Beyond that caution, side effects of fatty
acids appear to be mild and primarily involve the gastrointest-
inal tract (ie, nausea, diarrhea, and belching).
The bulk of the data support omega-3 fatty acids’ role in the
treatment of mood disorders. While data are promising for psy-
chiatric illness beyond affective disorders, it is premature to
routinely recommend omega-3 fatty acids as the primary treat-
ment for most other psychiatric disorders. However, given the
favorable side effect profile and cardiovascular benefits of
omega-3 fatty acids, they would appear to be safe for most
populations.
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